A Study Assessing Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter

Exclusion Criteria

• •Diagnosed with an arrhythmia requiring epicardial mapping
• •Study arrhythmia secondary to reversible cause, or secondary to electrolyte imbalance, thyroid disease, or non-cardiac cause
• •Atrial arrhythmias: participants with a left atrial size greater than (\>) 55 millimeters (mm)
• •Left Ventricular Ejection Fraction (LVEF) less than or equal to (\<=) 25 percent (%) for participants with ventricular arrhythmia
• •LVEF \<= 40% for participants with atrial arrhythmia
• •Documented intracardiac thrombus as detected on imaging within 24 hours prior to insertion of the investigational catheter
• •Contraindication to anticoagulation (that is heparin, warfarin, dabigatran)
• •History of blood clotting or bleeding abnormalities (example, hypercoagulable state)
• •Myocardial infarction within the past 2 months (60 days)
• •Documented thromboembolic event (including Transient Ischemic Attack \[TIA\]) within the past 12 months (365 days)
• •Uncontrolled heart failure or New York Heart Association (NYHA) function class IV
• •Implanted with a pacemaker or intracardiac cardiac defibrillator within the past 6 weeks (42 days)
• •Participants with known untreatable allergy to contrast media
• •Active illness or active systemic infection or sepsis
• •Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation
• •Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study
• •Participants that have ever undergone a percutaneous or surgical valvular cardiac procedure (that is, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)
• •Any cardiac surgery within the past 60 days (2 months) (includes Percutaneous Coronary Intervention \[PCI\])
• •Atrial septal closure within the past 6 weeks (42 days)
• •Presence of a condition that precludes vascular access
• •Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation
• •Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
• •Concurrent enrollment in an investigational study evaluating another device or drug